Desvenlafaxine Succinate Patent Expiration
Desvenlafaxine Succinate is Used for treating depression, including maintenance treatment of major depressive disorder. It was first introduced by Pf Prism Cv
Desvenlafaxine Succinate Patents
Given below is the list of patents protecting Desvenlafaxine Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pristiq | US8269040 | Derivatives of venlafaxine and methods of preparing and using the same | Jul 05, 2027 | Pf Prism Cv |
| Pristiq | US6673838 | Succinate salt of O-desmethyl-venlafaxine |
Mar 01, 2022
(Expired) | Pf Prism Cv |
| Pristiq | US6673838 | Succinate salt of O-desmethyl-venlafaxine |
Feb 11, 2022
(Expired) | Pf Prism Cv |
Desvenlafaxine Succinate's Family Patents
Explore Our Curated Drug Screens
Desvenlafaxine Succinate Generic API Manufacturers
Several generic applications have been filed for Desvenlafaxine Succinate. The first generic version for Desvenlafaxine Succinate was by Alembic Pharmaceuticals Ltd and was approved on Jun 29, 2015. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Jan 15, 2025.
Given below is the list of companies who have filed for Desvenlafaxine Succinate generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS LABS FL
Actavis Laboratories Fl Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2016 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2016 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Jul 29, 2016 |
2. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Sep 14, 2018 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
3. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Feb 16, 2016 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Feb 16, 2016 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Aug 28, 2017 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
4. LUPIN LTD
Lupin Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Apr 13, 2022 |
Manufacturing Plant Locations New
Lupin Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Lupin Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
5. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jan 15, 2025 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jan 15, 2025 |
6. MEDICAP LABS
Medicap Laboratories has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Medicap Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | May 7, 2019 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | May 7, 2019 |
7. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 2 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Discontinued | ORAL | N/A | Jun 29, 2015 |
| EQ 50MG BASE | tablet, extended release | Discontinued | ORAL | N/A | Jun 29, 2015 |
8. RUBICON
Rubicon Research Private Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Rubicon.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Jun 29, 2015 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Dec 7, 2023 |
Manufacturing Plant Locations New
Rubicon's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Rubicon as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| Canada |
| |||||
| India |
| |||||
9. YICHANG HUMANWELL
Yichang Humanwell Pharmaceutical Co Ltd has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Yichang Humanwell.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 1, 2018 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 1, 2018 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 13, 2020 |
Manufacturing Plant Locations New
Yichang Humanwell's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Yichang Humanwell as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| China |
| |||
10. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Desvenlafaxine Succinate. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 11, 2017 |
| EQ 50MG BASE | tablet, extended release | Prescription | ORAL | AB | Oct 11, 2017 |
| EQ 25MG BASE | tablet, extended release | Prescription | ORAL | AB | Nov 30, 2022 |